Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

Jody Groenendyk

dblp:155/1362 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
0since 2021 · last 2014
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%

Topics — the 3 heaviest of 3, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › drug discovery › target identification
drug target identification
0.212014
Human structural proteome-wide characterization of Cyclosporine A targets · Bioinform. 2014
Bioinformatics and computational biology › drug discovery › computational drug discovery
protein-ligand interaction prediction
0.212014
Human structural proteome-wide characterization of Cyclosporine A targets · Bioinform. 2014
Bioinformatics and computational biology › proteomics
structural proteomics
0.112014
Human structural proteome-wide characterization of Cyclosporine A targets · Bioinform. 2014

Methods — techniques the papers use, named apart from their topics

surface plasmon resonance · 0.2molecular dynamics · 0.2molecular docking · 0.2enzymatic assay · 0.2
YearPublicationVenuePosition
2014 Human structural proteome-wide characterization of Cyclosporine A targets
abstract
MOTIVATION: Off-target interactions of a popular immunosuppressant Cyclosporine A (CSA) with several proteins besides its molecular target, cyclophilin A, are implicated in the activation of signaling pathways that lead to numerous side effects of this drug. RESULTS: Using structural human proteome and a novel algorithm for inverse ligand binding prediction, ILbind, we determined a comprehensive set of 100+ putative partners of CSA. We empirically show that predictive quality of ILbind is better compared with other available predictors for this compound. We linked the putative target proteins, which include many new partners of CSA, with cellular functions, canonical pathways and toxicities that are typical for patients who take this drug. We used complementary approaches (molecular docking, molecular dynamics, surface plasmon resonance binding analysis and enzymatic assays) to validate and characterize three novel CSA targets: calpain 2, caspase 3 and p38 MAP kinase 14. The three targets are involved in the apoptotic pathways, are interconnected and are implicated in nephrotoxicity.
Gang Hu 0005, Jody Groenendyk, Khaled H. Barakat, Marcin J. Mizianty, Jishou Ruan, Marek Michalak, Lukasz A. Kurgan
Bioinform.3